His primary scientific interests are in Internal medicine, Endocrinology, Cholesterol, Odds ratio and Prospective cohort study. His Internal medicine research is multidisciplinary, relying on both Population study and Cardiology. His Endocrinology research includes themes of Mendelian randomization and Risk factor.
His Cholesterol study deals with C-reactive protein intersecting with Rosuvastatin Calcium and Rosuvastatin. His Odds ratio study also includes
Internal medicine, Endocrinology, Population study, Hazard ratio and Odds ratio are his primary areas of study. His Internal medicine research integrates issues from Oncology and Cardiology. His Endocrinology study frequently links to related topics such as Risk factor.
Børge G. Nordestgaard combines subjects such as Gastroenterology, COPD, Cohort study and Body mass index with his study of Population study. His Hazard ratio study combines topics from a wide range of disciplines, such as Proportional hazards model, Prospective cohort study and Surgery. As a part of the same scientific family, Børge G. Nordestgaard mostly works in the field of Odds ratio, focusing on Mendelian randomization and, on occasion, Mendelian Randomization Analysis and Confounding.
Børge G. Nordestgaard mainly investigates Internal medicine, Population study, Hazard ratio, Cholesterol and Myocardial infarction. Børge G. Nordestgaard has researched Internal medicine in several fields, including Endocrinology, Oncology and Cardiology. His work in the fields of Endocrinology, such as Very low-density lipoprotein and Diabetes mellitus, intersects with other areas such as Context.
The concepts of his Population study study are interwoven with issues in Body mass index, Cohort study, Gastroenterology, Confidence interval and Disease. His Hazard ratio research focuses on Prospective cohort study and how it relates to Epidemiology. The study incorporates disciplines such as Stroke, Statin, Interquartile range and Number needed to treat in addition to Myocardial infarction.
Børge G. Nordestgaard mainly focuses on Internal medicine, Population study, Myocardial infarction, Lipoprotein and Cholesterol. His Internal medicine research incorporates elements of Gastroenterology and Oncology. Børge G. Nordestgaard interconnects Blood pressure, FEV1/FVC ratio, Number needed to treat, Systemic inflammation and Confounding in the investigation of issues within Population study.
His Myocardial infarction research includes themes of Stroke, Lower risk, Confidence interval and Biomarker. His study in Lipoprotein is interdisciplinary in nature, drawing from both Risk factor and Apolipoprotein B. His Cholesterol study contributes to a more complete understanding of Endocrinology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M Ridker;Eleanor Danielson;Jacques Genest;Antonio M. Gotto.
The New England Journal of Medicine (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Paul M. Ridker;Eleanor Danielson;Francisco A. H. Fonseca;Jacques Genest.
Obstetrical & Gynecological Survey (2009)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Børge G. Nordestgaard;Marianne Benn;Peter Schnohr;Anne Tybjærg-Hansen.
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton;Karen A. Pooley;Alison M. Dunning;Paul D. P. Pharoah.
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society
Borge G. Nordestgaard;M. John Chapman;Steve E. Humphries;Henry N. Ginsberg.
European Heart Journal (2013)
Lipoprotein(a) as a cardiovascular risk factor: current status
Børge G. Nordestgaard;M. John Chapman;Kausik Ray;Jan Borén.
European Heart Journal (2010)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A Ference;Henry N Ginsberg;Ian T. Graham;Kausik K Ray.
European Heart Journal (2017)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M John Chapman;Henry N Ginsberg;Pierre Amarenco;Felicita Andreotti.
European Heart Journal (2011)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
Paul M Ridker;Eleanor Danielson;Francisco Ah Fonseca;Jacques Genest.
The Lancet (2009)
Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.
Pia R. Kamstrup;Anne Tybjærg-Hansen;Rolf Steffensen;Børge G. Nordestgaard.
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: